Option chain shows key data for Applied DNA Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Applied DNA Sciences.

Applied DNA Sciences (NASDAQ:APDN) Stock, Option Chain

Applied DNA Sciences

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

Wall Street

Equities

News

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

APDN

CRVS

NUKK

PRZO

QUBT

U.S. stock futures climbed on Wednesday as Wall Street awaits the Fed&#39;s final interest rate decision and its monetary policy forecasts for 2025.

US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Earnings

AUID

CERO

COMM

EFSH

FSBW

NIVF

PRTG

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

micron-ext-building

General Mills, Micron Technology And 3 Stocks To Watch Heading Into Wednesday

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences Inc

Offerings

Press Releases

Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial  for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

Applied DNA Reschedules Investor Update Call in Observance of the  National Day of Mourning in Recognition of the Passing of  Former President Jimmy Carter

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Applied DNA Reminds Shareholders to Vote Ahead of  Special Meeting on February 14

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Applied DNA Reports First Quarter Fiscal 2025  Financial Results and Highlights Operational Progress

Comments

Applied DNA Sciences

Applied DNA Sciences (APDN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga